SANDOMENICO C, FILIPPELLI G, MASSIDDA B, PUTZU C, NATALE D, PALMERI S, et al. (2006). “OXXEL (Oxaliplatin plus Xeloda) versus OXAFAFU (Oxaliplatin plus folinic acid-modulated 5-fluorouracil i.v. bolus) every 2 weeks in metastatic colorectal carcinoma (MCC): preliminary safety and activity analysis”. ??????? it.cilea.surplus.oa.citation.tipologie.CitationProceedings.prensentedAt ??????? 8th National Congress of Medical Oncology.

“OXXEL (Oxaliplatin plus Xeloda) versus OXAFAFU (Oxaliplatin plus folinic acid-modulated 5-fluorouracil i.v. bolus) every 2 weeks in metastatic colorectal carcinoma (MCC): preliminary safety and activity analysis”

PALMERI, Sergio;
2006-01-01

8th National Congress of Medical Oncology
2006
abs D35
SANDOMENICO C, FILIPPELLI G, MASSIDDA B, PUTZU C, NATALE D, PALMERI S, et al. (2006). “OXXEL (Oxaliplatin plus Xeloda) versus OXAFAFU (Oxaliplatin plus folinic acid-modulated 5-fluorouracil i.v. bolus) every 2 weeks in metastatic colorectal carcinoma (MCC): preliminary safety and activity analysis”. ??????? it.cilea.surplus.oa.citation.tipologie.CitationProceedings.prensentedAt ??????? 8th National Congress of Medical Oncology.
Proceedings (atti dei congressi)
SANDOMENICO C; FILIPPELLI G; MASSIDDA B; PUTZU C; NATALE D; PALMERI S; MAIORINO L; CONDEMI G; LEO S; GAMBARDELLA A COMELLA P
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10447/12172
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 0
social impact